ClinicalTrials.gg

Program

T3D-959

Also written as “15mg T3D-959”, “30 mg T3D-959” and “45 mg T3D-959”.

Its studies are mostly in Alzheimer Disease, led by T3D Therapeutics.

Furthest: phase 3, since Apr 14, 20253 company-led studies, 1 open or runningNext primary completion: Apr 2031 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
T3D Therapeutics31 open or runningphase 3since Apr 14, 2025Jul 28, 2015Apr 2031phase 3 · NCT06964230

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2015First study: phase 2 study in Alzheimer DiseaseFirst studyNCT02560753 · 36 enrolled · United States
  2. Jan 24, 2020Phase 2 study in Alzheimer DiseaseNCT04251182 · 250 enrolled · United States
  3. Apr 14, 2025Phase 3 study in Alzheimer DiseaseNCT06964230 · 376 planned · United States

Ahead

  1. Apr 2031Primary completion: phase 3 study in Alzheimer DiseaseNCT06964230

TargetBeta

PPARD →PPARG →read by rule
“Peroxisome proliferator-activated receptor delta agonist; Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
chiglitazarruleChipscreen Biosciencesphase 39
lanifibranorinventiva-pharmaphase 36

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06964230Alzheimer Disease · United States3Not yet recruitingApr 2031376
NCT04251182Alzheimer Disease · United States2CompletedJan 20, 2023250
NCT02560753Alzheimer Disease · United States2CompletedMay 30, 201636

How it is read

Names in the registry

  • “T3D-959”, 2 entries
  • “15mg T3D-959”, 1 entry
  • “30 mg T3D-959”, 1 entry
  • “45 mg T3D-959”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.